CD123: a paradigmatic target for immunotherapeutic treatment modalities

Publisher: La Merie Publishing
Pages: 83
Format: PDF
Product Line:
Brief Report
Product Code: LMBR0013
Release Date: August of 2016

700.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

CD123: a paradigmatic target for immunotherapeutic treatment modalities

This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3Rα) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.

Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and devleopment of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:

  • Fc-engineered antibodies;
  • Immunotoxins;
  • Antibody-drug conjugates;
  • T-cell redirecting bispecific antibodies;
  • Chimeric Antigen Receptor (CAR) engineered T-cells.

This report describes the profiles of 16 different anti-CD123 immunotherapeutics based on different treatment modalities. The FDA recently acknowledged the anti-CD123 treatment approach by granting Breakthrough Therapy designation to the immunotoxin SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 is the most advanced of 15 different anti-CD123 immunotherapeutis, seven of them are in earlier clinical develoment and further four are being prepared for clinical evaluation.

This report describes and analyzes the

  • Target Background & Scientific Rationale
  • Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
  • Clinical Experience with CD123-Targeted Treatment Modalities
  • Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD123 Immunotherapeutics
  • Company Profiles

CD123: a paradigmatic target for immunotherapeutic treatment modalities

Table of Contents

Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:

  • Immunotoxins
  • Naked Antibody
  • Fc-Engineered Antibodies
  • Antibody-Drug Conjugates
  • T-Cell Redirecting Bispecific Antibodies
  • Anti-CD123 CAR T-Cells

Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top